The promise of in vivo gene therapy has been constrained by the limits of delivery, holding back the full potential of transformative science.
STRM.BIO is redefining what’s possible, enabling therapies to be designed around disease biology, instead of delivery tradeoffs.
STRM.BIO megakaryocyte-derived extracellular vesicles (STRM MVs) offer a fundamentally different approach for gene therapy delivery. STRM MVs harness cell-type specific biological attributes to target and deliver complex genetic cargoes preferentially to bone marrow.
We have developed a scalable system to enable safe in vivo delivery of genetic medicines that were previously impractical or impossible, with an initial focus on rare hematological diseases and CAR-T therapies.
By removing the limitations of viral and synthetic delivery systems, STRM.BIOs MV platform enables new in vivo approaches including gene editing, RNA therapeutics, and immune cell engineering.
BUILT TO TARGET WHAT MATTERS
Leveraging innate tropism to reach hematopoietic stem and progenitor cells, without the need for genetic or chemical engineering
REPEAT DOSING CAPABILITY
A non-viral, immune-privileged, allogeneic platform that supports short and long-term treatment strategies
ENGINEERED FOR VERSATILITY
Potential to load DNA and RNA payloads, with multiplexing capabilities
READY TO SCALE
Robust manufacturing designed for seamless transition from clinic to commercial production